Cargando…
Hyperthyroidism Prevalence in China After Universal Salt Iodization
BACKGROUND: Universal salt iodization (USI) was implemented in mainland China in 1996. The prevalence of hyperthyroidism and its risk factors now require examination. METHODS: Data were acquired from a nationwide Thyroid, Iodine, and Diabetes Epidemiological survey (TIDE 2015–2017) of 78,470 subject...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194401/ https://www.ncbi.nlm.nih.gov/pubmed/34122333 http://dx.doi.org/10.3389/fendo.2021.651534 |
_version_ | 1783706410370990080 |
---|---|
author | Wang, Chuyuan Li, Yongze Teng, Di Shi, Xiaoguang Ba, Jianming Chen, Bing Du, Jianling He, Lanjie Lai, Xiaoyang Li, Yanbo Chi, Haiyi Liao, Eryuan Liu, Chao Liu, Libin Qin, Guijun Qin, Yingfen Quan, Huibiao Shi, Bingyin Sun, Hui Tang, Xulei Tong, Nanwei Wang, Guixia Zhang, Jin-an Wang, Youmin Xue, Yuanming Yan, Li Yang, Jing Yang, Lihui Yao, Yongli Ye, Zhen Zhang, Qiao Zhang, Lihui Zhu, Jun Zhu, Mei Shan, Zhongyan Teng, Weiping |
author_facet | Wang, Chuyuan Li, Yongze Teng, Di Shi, Xiaoguang Ba, Jianming Chen, Bing Du, Jianling He, Lanjie Lai, Xiaoyang Li, Yanbo Chi, Haiyi Liao, Eryuan Liu, Chao Liu, Libin Qin, Guijun Qin, Yingfen Quan, Huibiao Shi, Bingyin Sun, Hui Tang, Xulei Tong, Nanwei Wang, Guixia Zhang, Jin-an Wang, Youmin Xue, Yuanming Yan, Li Yang, Jing Yang, Lihui Yao, Yongli Ye, Zhen Zhang, Qiao Zhang, Lihui Zhu, Jun Zhu, Mei Shan, Zhongyan Teng, Weiping |
author_sort | Wang, Chuyuan |
collection | PubMed |
description | BACKGROUND: Universal salt iodization (USI) was implemented in mainland China in 1996. The prevalence of hyperthyroidism and its risk factors now require examination. METHODS: Data were acquired from a nationwide Thyroid, Iodine, and Diabetes Epidemiological survey (TIDE 2015–2017) of 78,470 subjects from 31 provinces. Iodine status, and thyroid hormones and antibodies were measured. RESULTS: After two decades of USI, the prevalence of overt hyperthyroidism (OH), Graves’ disease (GD), severe subclinical hyperthyroidism (severe SCH), and mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%, 0.22%, and 0.22%, respectively. OH and GD prevalence were higher in women than in men (OH: 1.16% vs. 0.64%, P<0.001; GD: 0.65% vs. 0.37%, P<0.001).Prevalence was significantly decreased after 60 years-of-age compared with 30–39 years-of-age (OH:0.61% vs. 0.81%, P<0.001; GD: 0.38% vs. 0.57%, P<0.001).Excessive iodine(EI) and deficient iodine(DI) were both related to increased prevalence of OH (odds ratio [OR] 2.09, 95% confidence interval [CI] 1.68–2.59; OR1.35, 95%CI 1.07–1.72, respectively); however, only deficient iodine was associated with increased prevalence of GD (OR1.67, 95%CI 1.30–2.15). Increased thyroid peroxidase antibody and thyroglobulin antibody levels were significantly associated with prevalence of OH and GD, but not severe SCH and mild SCH. Although hyperthyroidism was more prevalent in women, the association disappeared after adjusting for other factors such as antibody levels. CONCLUSION: OH and GD prevalences in mainland China are stable after two decades of USI. Iodine deficiency, elevated thyroid antibody levels, and middle age are the main risk factors for OH and GD. The severe SCH population, rather than the mild SCH population, shows similar characteristics to the OH population. |
format | Online Article Text |
id | pubmed-8194401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81944012021-06-12 Hyperthyroidism Prevalence in China After Universal Salt Iodization Wang, Chuyuan Li, Yongze Teng, Di Shi, Xiaoguang Ba, Jianming Chen, Bing Du, Jianling He, Lanjie Lai, Xiaoyang Li, Yanbo Chi, Haiyi Liao, Eryuan Liu, Chao Liu, Libin Qin, Guijun Qin, Yingfen Quan, Huibiao Shi, Bingyin Sun, Hui Tang, Xulei Tong, Nanwei Wang, Guixia Zhang, Jin-an Wang, Youmin Xue, Yuanming Yan, Li Yang, Jing Yang, Lihui Yao, Yongli Ye, Zhen Zhang, Qiao Zhang, Lihui Zhu, Jun Zhu, Mei Shan, Zhongyan Teng, Weiping Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Universal salt iodization (USI) was implemented in mainland China in 1996. The prevalence of hyperthyroidism and its risk factors now require examination. METHODS: Data were acquired from a nationwide Thyroid, Iodine, and Diabetes Epidemiological survey (TIDE 2015–2017) of 78,470 subjects from 31 provinces. Iodine status, and thyroid hormones and antibodies were measured. RESULTS: After two decades of USI, the prevalence of overt hyperthyroidism (OH), Graves’ disease (GD), severe subclinical hyperthyroidism (severe SCH), and mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%, 0.22%, and 0.22%, respectively. OH and GD prevalence were higher in women than in men (OH: 1.16% vs. 0.64%, P<0.001; GD: 0.65% vs. 0.37%, P<0.001).Prevalence was significantly decreased after 60 years-of-age compared with 30–39 years-of-age (OH:0.61% vs. 0.81%, P<0.001; GD: 0.38% vs. 0.57%, P<0.001).Excessive iodine(EI) and deficient iodine(DI) were both related to increased prevalence of OH (odds ratio [OR] 2.09, 95% confidence interval [CI] 1.68–2.59; OR1.35, 95%CI 1.07–1.72, respectively); however, only deficient iodine was associated with increased prevalence of GD (OR1.67, 95%CI 1.30–2.15). Increased thyroid peroxidase antibody and thyroglobulin antibody levels were significantly associated with prevalence of OH and GD, but not severe SCH and mild SCH. Although hyperthyroidism was more prevalent in women, the association disappeared after adjusting for other factors such as antibody levels. CONCLUSION: OH and GD prevalences in mainland China are stable after two decades of USI. Iodine deficiency, elevated thyroid antibody levels, and middle age are the main risk factors for OH and GD. The severe SCH population, rather than the mild SCH population, shows similar characteristics to the OH population. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8194401/ /pubmed/34122333 http://dx.doi.org/10.3389/fendo.2021.651534 Text en Copyright © 2021 Wang, Li, Teng, Shi, Ba, Chen, Du, He, Lai, Li, Chi, Liao, Liu, Liu, Qin, Qin, Quan, Shi, Sun, Tang, Tong, Wang, Zhang, Wang, Xue, Yan, Yang, Yang, Yao, Ye, Zhang, Zhang, Zhu, Zhu, Shan and Teng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Wang, Chuyuan Li, Yongze Teng, Di Shi, Xiaoguang Ba, Jianming Chen, Bing Du, Jianling He, Lanjie Lai, Xiaoyang Li, Yanbo Chi, Haiyi Liao, Eryuan Liu, Chao Liu, Libin Qin, Guijun Qin, Yingfen Quan, Huibiao Shi, Bingyin Sun, Hui Tang, Xulei Tong, Nanwei Wang, Guixia Zhang, Jin-an Wang, Youmin Xue, Yuanming Yan, Li Yang, Jing Yang, Lihui Yao, Yongli Ye, Zhen Zhang, Qiao Zhang, Lihui Zhu, Jun Zhu, Mei Shan, Zhongyan Teng, Weiping Hyperthyroidism Prevalence in China After Universal Salt Iodization |
title | Hyperthyroidism Prevalence in China After Universal Salt Iodization |
title_full | Hyperthyroidism Prevalence in China After Universal Salt Iodization |
title_fullStr | Hyperthyroidism Prevalence in China After Universal Salt Iodization |
title_full_unstemmed | Hyperthyroidism Prevalence in China After Universal Salt Iodization |
title_short | Hyperthyroidism Prevalence in China After Universal Salt Iodization |
title_sort | hyperthyroidism prevalence in china after universal salt iodization |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194401/ https://www.ncbi.nlm.nih.gov/pubmed/34122333 http://dx.doi.org/10.3389/fendo.2021.651534 |
work_keys_str_mv | AT wangchuyuan hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT liyongze hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT tengdi hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT shixiaoguang hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT bajianming hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT chenbing hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT dujianling hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT helanjie hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT laixiaoyang hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT liyanbo hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT chihaiyi hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT liaoeryuan hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT liuchao hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT liulibin hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT qinguijun hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT qinyingfen hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT quanhuibiao hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT shibingyin hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT sunhui hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT tangxulei hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT tongnanwei hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT wangguixia hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT zhangjinan hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT wangyoumin hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT xueyuanming hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT yanli hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT yangjing hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT yanglihui hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT yaoyongli hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT yezhen hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT zhangqiao hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT zhanglihui hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT zhujun hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT zhumei hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT shanzhongyan hyperthyroidismprevalenceinchinaafteruniversalsaltiodization AT tengweiping hyperthyroidismprevalenceinchinaafteruniversalsaltiodization |